SCHEMBL6977575

SCHEMBL6977575

CCOc1ccc(NC(=O)c2cnc3c(N)cccc3c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.56
RAB9A P51151 7/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
TP53 P04637 1/20 0.56
KMT2A Q03164 7/20 0.55
MEN1 O00255 5/20 0.55
P4HTM Q9NXG6 3/20 0.54
POLB P06746 3/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 1/20 0.52
APOBEC3A P31941 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
GAA P10253 1/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6537724 0.76 PSMD14 (0.50) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL2920230 0.75 NPC1 (0.74) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL5798244 0.73 RAB9A (0.72) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL31396781 0.73 NPC1 (1.00) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL6980589 0.72 P4HTM (0.48) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL7635847 0.72 NPC1 (0.84) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL30553441 0.72 PSMD14 (0.50) MAPTKDM4EALDH1A1
SCHEMBL27214185 0.72 PSMD14 (0.50) MAPTKDM4EALDH1A1
SCHEMBL8819992 0.72 KMT2A (0.64) NPC1RAB9ASMN1; SMN2TP53KMT2A
Iodide SCHEMBL30758616 0.71 NPC1 (0.82) NPC1RAB9ASMN1; SMN2TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 NPC1 292/4885RAB9A 1686/4885SMN1; SMN2 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.